UNSPSC 51312105: Epinastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H15N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFM415S5XL, chemically known as 9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepin-3-amine hydrochloride but more generally known as epinastine hydrochloride, which bears US NIH Compound Identifier 157313. European Medicines Agency schedules Epinastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01910MIG.

UNSPSC 51312105 Epinastine hydrochloride is a Commodity code in the pharmaceutical products taxonomy, but the recent opportunities recorded under it do not reflect purchases of epinastine hydrochloride specifically. Instead, the code shows state and local procurement activity for naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and pharmacy benefit programs. State and local issuing bodies pursuing these opportunities include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope of work centers on bulk procurement and distribution of pharmaceutical and medical products to support community health initiatives, emergency response systems, and state employee and retiree health plans. Vendors must typically meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and provide detailed product information including NDC codes and pricing across multiple net-pricing and WAC-minus formats.

The recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The MMCAP contract serves multiple state and local government facilities across Minnesota and Oregon. Vendors responding to these opportunities must provide unit pricing, comply with E-Verify and drug-free workplace requirements, and maintain specified insurance coverages including commercial general liability and professional liability.